Iturelix

Drug Profile

Iturelix

Alternative Names: Antide™; Nal-Lys-GnRH; ORF 23541

Latest Information Update: 25 Jan 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ortho-McNeil
  • Developer Bayer Schering Pharma; Ortho-McNeil
  • Class Antineoplastics; Contraceptives
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Cancer; Endometriosis; Female infertility; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 01 Nov 2004 Discontinued - Phase-II for Female infertility in Europe (unspecified route)
  • 01 Nov 2004 Discontinued - Preclinical for Benign prostatic hyperplasia in Switzerland (unspecified route)
  • 01 Nov 2004 Discontinued - Preclinical for Endometriosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top